These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 22296195)

  • 21. Adverse prognosis associated with the metabolic syndrome in established coronary artery disease: data from the EUROPA trial.
    Daly CA; Hildebrandt P; Bertrand M; Ferrari R; Remme W; Simoons M; Fox KM;
    Heart; 2007 Nov; 93(11):1406-11. PubMed ID: 17540689
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical implications of obesity with specific focus on cardiovascular disease: a statement for professionals from the American Heart Association Council on Nutrition, Physical Activity, and Metabolism: endorsed by the American College of Cardiology Foundation.
    Klein S; Burke LE; Bray GA; Blair S; Allison DB; Pi-Sunyer X; Hong Y; Eckel RH;
    Circulation; 2004 Nov; 110(18):2952-67. PubMed ID: 15509809
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Body composition, inflammation and thermogenesis in pathways to obesity and the metabolic syndrome: an overview.
    Dulloo AG; Montani JP
    Obes Rev; 2012 Dec; 13 Suppl 2():1-5. PubMed ID: 23107254
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Optimal medical treatment of cardiovascular risk factors: can we prevent the development of heart failure?
    Alba AC; Delgado DH
    Expert Rev Cardiovasc Ther; 2009 Feb; 7(2):147-57. PubMed ID: 19210211
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Metabolic syndrome, diabetes and cardiovascular events: current controversies and recommendations.
    Zarich SW
    Minerva Cardioangiol; 2006 Apr; 54(2):195-214. PubMed ID: 16778752
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The genetic basis of obesity and type 2 diabetes: lessons from the new zealand obese mouse, a polygenic model of the metabolic syndrome.
    Joost HG
    Results Probl Cell Differ; 2010; 52():1-11. PubMed ID: 20865367
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The impact of vitamin D deficiency on diabetes and cardiovascular risk.
    Baz-Hecht M; Goldfine AB
    Curr Opin Endocrinol Diabetes Obes; 2010 Apr; 17(2):113-9. PubMed ID: 20150805
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Metabolic syndrome pathophysiology and clinical presentation.
    Handelsman Y
    Toxicol Pathol; 2009 Jan; 37(1):18-20. PubMed ID: 19098117
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic impact of metabolic syndrome by different definitions in a population with high prevalence of obesity and diabetes: the Strong Heart Study.
    de Simone G; Devereux RB; Chinali M; Best LG; Lee ET; Galloway JM; Resnick HE;
    Diabetes Care; 2007 Jul; 30(7):1851-6. PubMed ID: 17440172
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Glycaemic variability using continuous glucose monitoring and endothelial function in the metabolic syndrome and in Type 2 diabetes.
    Buscemi S; Re A; Batsis JA; Arnone M; Mattina A; Cerasola G; Verga S
    Diabet Med; 2010 Aug; 27(8):872-8. PubMed ID: 20653743
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pathogenic potential of adipose tissue and metabolic consequences of adipocyte hypertrophy and increased visceral adiposity.
    Bays HE; González-Campoy JM; Bray GA; Kitabchi AE; Bergman DA; Schorr AB; Rodbard HW; Henry RR
    Expert Rev Cardiovasc Ther; 2008 Mar; 6(3):343-68. PubMed ID: 18327995
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Brain and cardiovascular diseases: common neurogenic background of cardiovascular, metabolic and inflammatory diseases.
    Szczepanska-Sadowska E; Cudnoch-Jedrzejewska A; Ufnal M; Zera T
    J Physiol Pharmacol; 2010 Oct; 61(5):509-21. PubMed ID: 21081794
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Type 2 diabetes mellitus: a cardiovascular perspective.
    Varughese GI; Tomson J; Lip GY
    Int J Clin Pract; 2005 Jul; 59(7):798-816. PubMed ID: 15963208
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Is visceral obesity the cause of the metabolic syndrome?
    Després JP
    Ann Med; 2006; 38(1):52-63. PubMed ID: 16448989
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The progression of cardiovascular risk to cardiovascular disease.
    Rosin BL
    Rev Cardiovasc Med; 2007; 8 Suppl 4():S3-8. PubMed ID: 17934392
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The metabolic and inflammatory profile in obese patients with chronic obstructive pulmonary disease.
    Stanciu S; Iordache M; Busuioceanu A; Tănăseanu G; Zamfir L; Mureşan M; Bogdan MA
    Rom J Intern Med; 2009; 47(2):123-32. PubMed ID: 20067162
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Metabolic syndrome, diabetes and coronary heart disease.
    Haffner SM
    Int J Clin Pract Suppl; 2002 Oct; (132):31-7. PubMed ID: 12425361
    [No Abstract]   [Full Text] [Related]  

  • 38. IGFBP-2 at the interface of growth and metabolism--implications for childhood obesity.
    Sabin MA; Russo VC; Azar WJ; Yau SW; Kiess W; Werther GA
    Pediatr Endocrinol Rev; 2011 Jun; 8(4):382-93. PubMed ID: 21972778
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Melatonin and the metabolic syndrome: a tool for effective therapy in obesity-associated abnormalities?
    Nduhirabandi F; du Toit EF; Lochner A
    Acta Physiol (Oxf); 2012 Jun; 205(2):209-23. PubMed ID: 22226301
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Biomarkers in cardiovascular disease: integrating pathophysiology into clinical practice.
    Parikh SV; de Lemos JA
    Am J Med Sci; 2006 Oct; 332(4):186-97. PubMed ID: 17031244
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.